



SOLARA
Active Pharma Sciences

Communication Address :
Solara Active Pharma Sciences Limited
"Batra Centre"
No. 28, Sardar Patel Road, Post Box 2630
Guindy, Chennai - 600 032, India
Tel : +91 44 43446700, 22207500
Fax : +91 44 22350278

December 14, 2018

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 541540

Scrip Code: SOLARA

Dear Sir / Madam,

Sub:- Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

We are enclosing herewith a press release issued by the Company titled:

"Solara Research Centre completes USFDA Inspection with zero 483s"

Thanking you,

Yours faithfully,
For Solara Active Pharma Sciences Limited


S. Hariharan
Executive Director & CFO



Encl:- as above

Solara Research Centre completes USFDA Inspection with zero 483s

Chennai, India – December 14, 2018: Solara Active Pharma Science Limited (Solara), a leading Active Pharmaceutical Ingredient provider today announced the successful completion of US FDA inspection at Solara Research Centre(SRC), Chennai with zero 483s inspectional observations.

Established in 2005, SRC is a state-of-the-art R&D centre with capabilities to develop niche products characterised by complex chemistry across the diverse therapeutic categories. The centre is equipped with high-end infrastructure with advanced analytical capabilities, strong IP assessment skills and global regulatory expertise. It is led by experienced technical leadership which has demonstrated significant strategic value for the customers and the partners. SRC is also an important pivot in Solara’s Contract Research and manufacturing services(CRAMS) vertical.

SRC was earlier inspected by USFDA as “Control Testing Laboratory” in December 2012 and August 2016.

About Solara

Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA) headquartered in Bengaluru, India offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services in over 75 countries. It has a manufacturing base comprising five API facilities in India with approvals including the USFDA, EU GMP, KFDA and PMDA in Japan.

Investor / Analyst contact

Dikshita Jain

Christensen Investor Relations

✉ djain@christensenir.com

☎ +91 22 4215 0210

Statutory contact

Murali Krishna S

Raghavan. V

✉ investors@solara.co.in

☎ +91 44 4344 6700

Disclaimer: Certain statements in this document that are not historical facts are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Solara Active Pharma Sciences Ltd will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.